30 closest matches · ranked by relevance
Influenza
Primary: Number of Participants With Laboratory-Confirmed Clinical Influenza, ITT Population — 7; 5 participants — p=0.772
Influenza
Primary: Number of Laboratory Confirmed Influenza Infections — 2; 1 infections — p=0.25
Pulmonary Disease, Chronic Obstructive · Bronchospasm · Influenza, Human
Primary: Number of Patients With Influenza — 3; 10; 2539; 93 patients
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
Aspergillosis; Pulmonary, Invasive (Etiology)
Primary: Number of Participants With IAA-infection at ICU Discharge — 2; 4 Participants
Influenza
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs — 40; 50 percentage of participants analyzed — p=0.046
Influenza A H3N2
Primary: Primary Efficacy Endpoint: The Area Under the Curve (AUC) of Total Symptom Score From Day 1 (Post Viral Challenge) to Day 8 (Quarantine Discharge). — 17956.5; 4502.6…
Influenza Viral Infections
Primary: Incidence of Symptomatic Influenza Infection — 6; 6; 16; 12 Participants — p=0.0331
Influenza, Human
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…
Influenza, Human
Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants
Influenza, Human
Primary: Percentage of Participants With Adverse Events — 40.0; 47.3; 25.7; 29.1 percentage of participants
Plasma Cell Neoplasm
Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants
Influenza · Acute Respiratory Infection · Influenza-like Illness
Primary: Number of Laboratory-confirmed Influenza Infections — .22; .14 infections
Influenza A · Influenza B
Primary: Time to Normalization of Respiratory Status (Primary Efficacy Population) — 7; 28 days — p=0.069
Influenza
Primary: Mean Symptom Severity Score During the 2015-2016 Influenza Season for Symptom Domains as Assessed Using the Influenza-Patient Reported Outcome (FLU-PRO™) Questionnaire…
Influenza, Human
Primary: Time to Clinical Response (TTCR) in Participants With Confirmed Influenza — 5.87; 5.14; 5.63 Days — p=0.25
Influenza
Primary: Duration of Influenza Illness — 4; 4 days
Influenza
Primary: Efficacy of an Investigational Vero Cell-derived Influenza Vaccine to Prevent Infection With an Influenza Virus That is Antigenically Similar to One of the Three Strains…
Influenza
Primary: MAARI Rate During the Epidemic Period (2007-2008) — 12503; 18998 Number of MAARI
Acute, Uncomplicated Human Influenza
Primary: Time to Alleviation of Symptoms (Kaplan-Meier Estimate) — 106.9; 91.1 hours — p=0.222
Influenza
Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
Influenza
Primary: Oseltamivir Carboxylate AUC12 (Area Under the Curve). — 6; 1; 3; 0 participants
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Influenza
Primary: Time to Clinical Stability (Kaplan-Meier Estimate) — 23.7; 37.0; 28.1 hours — p=0.306
Influenza · Seasonal Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 4; 12; 9; 8 Participants
Influenza
Primary: Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza — 28; 56; 35 participants
Influenza
Primary: Assess the Safety and Tolerability of a Single IV Dose of VIS410 in Participants With Uncomplicated Influenza Infection — 57.1; 34.7; 45.9; 26.0 percentage of participants
Influenza
Primary: Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Quadrivalent Influenza Vaccine or Fluzone® Trivalent…
Influenza A H3N2 · Influenza A H1N1
Primary: Frequency Counts and Percentage of Subjects With Adverse Events — 6; 6; 1; 3 Participants